medigraphic.com
Colegio de Medicos y Cirujanos República de Costa Rica

2014, Número 610

<< Anterior Siguiente >>

Rev Med Cos Cen 2014; 71 (610)


Actualización sobre el uso de Hipoglicemiantes orales para el tratamiento farmacológico en diabetes mellitus gestacional

García-Herrera E

Idioma: Español
Referencias bibliográficas: 27
Paginas: 225-229
Archivo PDF: 208.05 Kb.


RESUMEN

Las normas oficiales en el tratamiento farmacológico de la diabetes mellitus gestacional (DMG) indican el uso de insulina solamente; los hipoglicemiantes orales por lo general no se recomiendan de manera oficial, aunque muchos centros los han estado utilizando como agentes de primera línea en el tratamiento de pacientes que no alcanzan cifras optimas de control glicémico con dieta y ejercicio. No hay evidencia consistente de un aumento en efectos adversos tanto maternos como neonatales con el uso de glibenclamida o metformina comparados con insulina y cada vez son más los reportes, estudios observacionales, randomizados y comparativos que podrían en algún futuro ser utilizados para el desarrollo de nuevas guías de tratamiento, sin embargo, hasta la fecha, el uso de hipoglicemiantes orales en el tratamiento de la DMG, sigue siendo controversial.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. American Diabetes Association. Gestational diabetes mellitus. Diabetes Care. 2004; 27 (suppl 1): SS 88-S90

  2. Cheung NW. The management of gestational diabetes. Vasc Health Risk Manag 2009 5, 153–164.

  3. Coetzee E, Jackson WPU. Oral hypoglycaemics in the first trimester and fetal outcomes. S Afr Med J 1984

  4. Coustan DR. Pharmacological management of gestational diabetes: An overview. Diabetes Care 2007; 30:S206-S208.

  5. Feig DS, Briggs GG & Koren G. Oral antidiabetic agents in pregnancy and lactation: a paradigm shift? Annals of Pharmacotherapy 2007 41 1174– 1180.

  6. Galerneau F, Inzucchi SE. Diabetes mellitus in pregnancy. Obstet Gynecol Clin North Am 2004; 31: 907–33.

  7. Glueck CJ, Goldenberg N, Streicher P and Wang P. The contentious nature of gestational diabetes: diet, insulin, glyburide and metformin. Expert Opin Pharmacother 2002 3,1557–1568.

  8. HAPO Study Cooperative Research Group, Metzger BE, Lowe LP, et al. Hyperglycemia and adverse GARCIA: Uso de Hipoglicemiante s Orale s en Dia bete s Mellit us Gestacional 229 pregnancy outcomes. N Engl J Med 2008 358; 19

  9. Holt RI, Clarke P, Parry EC, Coleman MAG. The effectiveness of glibenclamide in women with gestational diabetes. Diabetes Obes Metab. 2008; 10:906–911.

  10. Homko CJ, Reece EA. Insulins and oral hypoglycemic agents in pregnancy. The Journal of Maternal- Fetal and Neonatal Medicine. 2006; 19:679–686

  11. Kjos, SL, et al. Gestational diabetes mellitus: the prevalence of glucose intolerance and diabetes mellitus in the first two months postpartum. Am. J. Obstet. Gynecol. 1990. 163:93-98.

  12. Langer, O, Conway, DL, Berkus, MD, Xenakis, EM, Gonzales, O. A comparison of glyburide and insulin in women with gestational diabetes mellitus. N. Engl. J. Med. 2000. 343:1134-1138.

  13. Langer O, Yogev Y, Xenakis EM, et al. Insulin and glyburide therapy: Dosage, severity level of gestational diabetes, and pregnancy outcome. Am J Obstet Gynecol 2005; 192:134- 139.

  14. Langer O. Management of gestational diabetes: pharmacologic treatment options and glycemic control. Endocrinol Metab Clin N Am. 2006; 35:53-78.

  15. Langer O. Oral anti-hyperglycemic agents for the management of gestational diabetes mellitus. Obstet Gynecol Clin North Am 2007; 34:255-274.

  16. Langer O. When diet fails: insulin and oral hypoglycemic agents as alternatives for the management of gestational diabetes mellitus. J Matern Fetal Neonatal Med. 2002; 11:218–25

  17. Lee-Parritz A. Contemporary management of gestational diabetes. Current Opinion in Endocrinology, Diabetes and Obesity 2011, 18(6):395-400.

  18. Maymone AC, Baillargeon JP, Menard J and Ardilouze JL. Oral hypoglycemic agents for gestational diabetes mellitus? Expert Opin Drug Saf 2011 10(2):227-238.

  19. Nicholson W, Bolen S, Witkop CT, Neale D, Wilson L, Bass E. Benefits and risks of oral diabetes agents compared with insulin in women with gestational diabetes: a systematic review. Obstet Gynecol. 2009;113:193–205.

  20. Notelowitz M. Sulphonylurea therapy in the treatment of the pregnant diabetic. S Afr Med J 1971; 45: 226-9.

  21. Paglia MJ, Coustan DR. The use of oral antidiabetic medications in gestational diabetes mellitus. Curr Diab Rep 2009. Aug;9(4):287-290.

  22. Pollex EK, Feig DS, Koren G. Oral hypoglycemic therapy: understanding the mechanisms of transplacental transfer. J Matern Fetal Neonatal Med. 2010 Mar; 23(3):224-8

  23. Ramos GA, Jacobson GF, Kirby RS, et al. Comparison of glyburide and insulin for the management of gestationial diabetes with markedly elevated oral glucose challenge test and fasting hyperglycemia. J Perinatol. 2007; 27:262–267.

  24. Ray JG, O’Brien TE, Chan WS. Preconception care and the risk of congenital anomalies in the offspring of women with diabetes mellitus: a meta-analysis. QJM 2001; 94:435

  25. Rowan JA, Hague WM, Gao W, Battin MR, Moore MP. Metformin versus insulin for the treatment of gestational diabetes. N Engl J Med 2008; 358:2003-2015.

  26. Silva JC, Fachin DR, Coral ML, Bertini AM. Perinatal impact of the use of metformin and glyburide for the treatment of gestational diabetes mellitus. J Perinat Med. 2012 Jan 10; 40(3):225-8.

  27. Tran ND. Oral hypoglycemic agents in pregnancy. Obst Gynecol Surv 2004; 59(6):456-63.




2020     |     www.medigraphic.com